Pharmaceutical Technology

JULY 29, 2022

In 2013, the US Food and Drug Administration (FDA) approved Ravicti (glycerol phenylbutyrate), manufactured by Hyperion Therapeutics, which has since then been acquired by Horizon Pharma. Drugs for dialysis, amino acid supplements, and drugs which convert blood ammonia are marketed right now as the go-to urea cycle disorder treatments.

RNA 245

RNA Gene Expression Gene Gene Therapy 245

XTalks

MAY 29, 2024

The company focuses heavily on its product and business development and prioritizes its environmental and social responsibilities. Looking ahead, Pfizer plans to leverage its expertise in protein engineering and medicinal chemistry to further develop Seagen’s antibody-drug conjugate (ADC) technology. Vertex reported $9.87

Medicine 52

Medicine Marketing FDA Approval Development 52

Pharmaceutical Technology

DECEMBER 22, 2022

The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects. What all the ranked entities have in common is the demonstration of new concepts not just within their own business but in the sector as a whole.

Insulin 130

Insulin Production Development Genetics 130

The Pharma Data

DECEMBER 8, 2020

AbCellera’s AI-powered antibody discovery platform speeds the otherwise lengthy and grueling process by analyzing the database of natural immune systems to find antibodies that can be developed into drugs. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost. Sigilon Therapeutics

RNA 52

RNA Antibody Life Science Protein 52

Drug Discovery World

APRIL 27, 2023

The abundant networking opportunities with world-class researchers here not only help grow our customer base but are also useful for recruitment or identifying potential collaborators for new software integrations or developments.” As a well- known life science hub, we will benefit from the pool of talent concentrated in RTP.

Life Science 52

Life Science Drugs Research Gene Splicing 52

pharmaphorum

JANUARY 28, 2021

In March 2020, the FDA expanded the biosimilar category to include 90 additional molecules, meaning there are now more therapies that can serve as reference products for biosimilars. This is significant because it opens several therapeutic areas for biosimilar development and, ultimately, increased competition. About the author.

Marketing 119

Marketing Insulin HR Production 119

Drug Discovery World

FEBRUARY 24, 2023

Abbey Vangeloff is the Director of Business Development, Life Sciences, at Yahara Software. She finds that marrying that with past iterations of software development, where the software is highly deterministic, is a whole discipline in and of itself. She will be chairing a session at SLAS2023.

Life Science 52

Life Science Drugs Bioinformatics Development 52

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

SEPTEMBER 27, 2022

While a rumoured takeover by Merck & Co has yet to materialise, Seagen is getting on with its own business development, including a just-agreed licensing deal for a cancer immunotherapy developed by Dutch biotech Lava Therapeutics.

Licensing 111

Licensing Licensing FDA Approval Clinical Trials 111

The Pharma Data

AUGUST 3, 2021

billion in acquired in-process research & development (acquired IPR&D) associated with our acquisition of Five Prime Therapeutics, partially offset by increased revenues. pts Research & Development $ 1,082 $ 964 12% $ 1,036 $ 936 11% % of product sales 17.7% GAAP earnings per share (EPS) decreased 73% to $0.81 39.3% (25.8)

Sales 52

Sales Production Antibody Development 52

The Pharma Data

NOVEMBER 5, 2020

FDA accepted for priority review Libtayo ® (cemiplimab-rwlc) for both advanced non-small cell lung cancer and basal cell carcinoma. FDA approved Inmazeb for Ebola ( Zaire ebolavirus). NASDAQ: REGN ) today announced financial results for the third quarter of 2020 and provided a business update. Business Highlights.

Sales 52

Sales Production Manufacturing Antibody 52

XTalks

APRIL 21, 2023

The company claimed to have developed a revolutionary blood testing technology that could detect a wide range of diseases with just a few drops of blood. Theranos’ groundbreaking developments received many patents. And in 2015 the US Food & Drug Administration (FDA) approved an assay on Theranos’ proprietary technology.”

Life Science 98

Life Science Trials Production Compliance 98

The Pharma Data

NOVEMBER 5, 2020

resolving patent litigation brought in response to Teva’s Abbreviated New Drug Application, seeking approval to market a generic version of Xtampza ER prior to the expiration of Collegium’s applicable patents. FDA approval, and customary exceptions). Research and development. . Total cost of products revenues. .

Production 52

Production Marketing Sales Manufacturing 52

Drug Discovery World

SEPTEMBER 16, 2022

W here globally is innovation occurring and what factors – industry, regulatory, and academia – are helping developers get their products to market? There are a number of areas in the UK which are recognised as hubs for developers the sector. The UK stands as one of the key markets for cell and gene therapies.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

The Pharma Data

AUGUST 6, 2020

Research and development expenses increased 90% to $2.5 FDA) approval of Opdivo (nivolumab) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. Research and development expense.

Production 52

Production Branding Marketing Licensing 52

The Pharma Data

MAY 4, 2021

to $3.65, Primarily Reflecting Updates to Anticipated Contributions from BNT162b2 Partially Offset by Additional R&D Expenses for Vaccines to Protect Against COVID-19 as Well as Other mRNA-Based Development Programs and COVID-19 Antivirals. Raises Full-Year 2021 Guidance (3) for Revenues to a Range of $70.5 previously $59.4

Vaccination 40

Vaccination Vaccine Production Sales 40